Navigation Links
Significant Generic Erosion Will Cause Sales of Dyslipidemia Drugs to Decline by $3.6 Billion by 2016
Date:3/19/2008

Statins Will Continue to Dominate Market Despite Patent Expiries and Increased Use of Fixed-Dose Combinations, According to a New Report from

Decision Resources

WALTHAM, Mass., March 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of dyslipidemia therapies will decline from $28 billion in 2006 to $24.4 billion in 2016 owing to significant generic erosion, triggered particularly by the 2006 U.S. patent expiry of Merck's Zocor and the U.S. and European patent expiries of Pfizer's Lipitor beginning in 2010.

The new Pharmacor report entitled Dyslipidemia finds that statins will continue to dominate the dyslipidemia drug market by claiming more than 70 percent patient share in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. However, the sales share of statins will decline from $21 billion in 2006 to $7.8 billion in 2016 owing to generic erosion and greater use of fixed-dose combination therapies that offer dual modes of action and/or modulate high-density lipoprotein (HDL) in addition to low- density lipoprotein (LDL) cholesterol. The fixed-dose combinations class will capture 30 percent of the dyslipidemia market in 2016.

The report also finds that physicians will increasingly prescribe treatment aimed at aggressive LDL targets in high-risk patients, which will benefit more potent agents such as AstraZeneca's Crestor and add-on therapies such as Merck/Schering-Plough's Zetia/Ezetrol. Aggressive treatment will also boost uptake of novel LDL-lowering therapies such as lapaquistat, Takeda's novel squalene synthase inhibitor, which will be used in polypharmacy regimens.

"Although statins are entrenched as the first-line therapy of choice for the vast majority of dyslipidemia patients and have achieved success in lowering both LDL and the risk of heart attacks, the prevalence of both coronary heart disease and mortality remain unacceptably high," said Donny Wong, Ph.D., principal analyst at Decision Resources. "As a result, the medical community is increasingly targeting non-LDL lipid abnormalities, and despite the recent discontinuation of Pfizer's torcetrapib in Phase III development, physicians believe that well-tolerated therapies that target low or dysfunctional HDL can still play a vital role in primary and secondary prevention."

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Carnegie Mellon study shows just listening to cell phones significantly impairs drivers
2. NeurogesX to Present at Susquehanna Financial Groups 2nd Annual SIGnificant Options in Healthcare Conference
3. Novavax CEO to Present at Susquehannas Second SIGnificant Options in Healthcare Conference
4. Abaxis, Inc. to Present at the Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
5. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
6. Advanced Life Sciences to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference
7. Significant Growth for Pinstripe Leads to Need for Larger Facility
8. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
9. AAAS symposium to address significant effects of the male parent in reproductive success
10. Peter G. Peterson Commits $1 Billion Toward Solving Americas Most Significant Economic Challenges
11. Surprising New Research Indicates that Significant Numbers of Children as Young as 11 are Engaging in Sexual Activity and that Dating Violence and Abuse are Part of Their Relationships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... Northern California ... Primary Care Spring Symposium on April 1, 2017 in Santa Rosa. This well-attended ... and healthcare providers an opportunity to learn about cutting edge treatments, to collaborate, ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... candidates to serve on its Accreditation and Standards Committees to support the ... is improving image quality and reducing patient radiation dose,” reports Eliot Siegel, ...
(Date:4/21/2017)... ... April 21, 2017 , ... BrightStar Care Salt Lake City, a home care ... Utah (APCUT) and has appointed Rex Wheeler as its new Director of Business Development. ... agency and our ability to provide quality care to the community,” said Tammara Brown, ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... world leaders in hopes of squashing a global crisis with solution to peace plan. Yisrayl ... to work because the plan is given by the Creator Himself. , Yisrayl says ...
(Date:4/21/2017)... ... April 21, 2017 , ... During April 21-23, Super-Sod will join ... This festival offers entertainment for everyone — from the avid gardener to the landscape ... very high quality event held in a grand venue, and we are certainly looking ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... Inc ., a digital health company focused on modernizing and ... $25 million in Series B funding led by Qiming US ... Seattle that is part of a broader family ... included participation from SR One , who led ZappRx,s ... Google Ventures). As part of the financing, Mark McDade ...
Breaking Medicine Technology: